QR-Code

Melanoma-Derived iPCCs Show Differential Tumorigenicity and Therapy Response

A point mutation in the BRAF gene, leading to a constitutively active form of the protein, is present in 45%–60% of patients and acts as a key driver in melanoma. Shortly after therapy induction, resistance to MAPK pathway-specific inhibitors develops, indicating that pathway inhibition is circumven...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Mathias Bernhardt, Daniel Novak, Yassen Assenov, Elias Orouji, Nathalie Knappe, Kasia Weina, Maike Reith, Lionel Larribere, Christoffer Gebhardt, Christoph Plass, Viktor Umansky, Jochen Utikal
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2017-05-01
Schriftenreihe:Stem Cell Reports
Schlagworte:
melanoma
reprogramming
BRAF
therapy resistance
iPSC
iPCC
cancer
stem cells
induced pluripotency
inhibitor
Online-Zugang:http://www.sciencedirect.com/science/article/pii/S2213671117301133
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge